Overcoming T Cell Therapy Barriers with Engineered Proteins – The Scientist

This webinar will be hosted live and available on-demand

Tuesday, September 13 20222:30 PM Eastern Time (11:30 AM PT)

The tumor microenvironment can severely diminish adoptive T cell therapy efficacy by expressing ligands that activate T cell inhibitory receptors and by downregulating costimulatory ligand expression. To address these issues, researchers developed fusion proteins (FPs) that combine the ectodomain of one receptor with a different intracellular costimulatory signaling domain. Using in vitro assays, including the Incucyte serial killing over-time (SKO) assay, they evaluated T cell engineering strategies in persistence and survival studies.

In this LabTools webinar brought to you by Sartorius, Shannon Oda will discuss how pairing different extracellular and intracellular domains in FPs confers different attributes to therapeutic T cells.

Topics to be covered

Shannon K. Oda, PhDPrincipal InvestigatorSeattle Childrens Research InstituteAssistant ProfessorDepartment of Pediatrics Division of Hematology/Oncology University of Washington School of Medicine

See the rest here:
Overcoming T Cell Therapy Barriers with Engineered Proteins - The Scientist